News

Public · Published

Canaccord Genuity maintains Biohaven at Buy, raises price target to $32 from $21

Canaccord Genuity kept its Buy rating on Biohaven and raised its price target to $32 from $21. The new target is 52.4% higher than the previous target and implies 107.5% upside from Biohaven's October 30 closing price of $15.42.

Published:

Updated:

What happened

Canaccord Genuity kept its Buy rating on Biohaven and raised its price target to $32 from $21. The new target is 52.4% higher than the previous target and implies 107.5% upside from Biohaven’s October 30 closing price of $15.42.

Confirmed

Global impact / market context

The higher target signals that Canaccord sees more potential value in Biohaven shares while keeping its positive rating. If investors act on that view, buying could support the share price, but the target is an analyst estimate, not a guaranteed outcome or a change to the company’s business results.

Analyst inference

This update changes an analyst’s stated valuation view, not Biohaven’s reported operations, revenue, costs, or cash available. The article gives no explanation for the higher target, so it does not establish what assumptions changed or whether other analysts share Canaccord’s outlook.

Analyst inference

What to watch

  1. Check whether Canaccord later explains the assumptions behind its $32 target, since the article does not say what prompted the increase or identify expected business changes. Analyst inference
  2. Compare subsequent analyst ratings and targets for Biohaven to see whether Canaccord’s higher valuation is shared or remains a distinct opinion. Analyst inference
  3. Watch Biohaven’s future company disclosures for operating results or plans that could support or challenge the optimism implied by Canaccord’s Buy rating. Analyst inference

Evidence

  • Original source link unavailable